Diazepam Intensol

Athetosis, Lockjaw, Syndrome + 11 more

Treatment

20 Active Studies for Diazepam Intensol

What is Diazepam Intensol

Diazepam

The Generic name of this drug

Treatment Summary

Diazepam is a medication used to treat severe anxiety, insomnia, seizures, muscle spasms, and alcohol withdrawal. It helps to relax the body and can be administered in different ways. In 2015-2016, an auto-injector was developed and approved by the US FDA that administers diazepam quickly and easily through a subcutaneous injection, allowing for fast and consistent absorption of the drug. This is a useful tool to help patients with epilepsy manage their seizures.

Valium

is the brand name

Diazepam Intensol Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Valium

Diazepam

1963

289

Effectiveness

How Diazepam Intensol Affects Patients

Diazepam is a benzodiazepine that helps reduce anxiety, make you feel sleepy, relax your muscles, prevent seizures, and helps you forget things. Most of these effects are caused by making it easier for the neurotransmitter GABA to do its job in the brain. GABA is a chemical that helps keep the brain calm.

How Diazepam Intensol works in the body

Diazepam is a drug that helps relieve tension, muscle spasms, and seizures. It does this by interacting with certain parts of the brain and spinal cord, which increases the calming effects of GABA. GABA helps with sleep, anxiety, memory, and controlling overactive nerves.

When to interrupt dosage

The quantity of Diazepam Intensol is contingent upon the diagnosed affliction, including Muscle Tissue, Seizures and Anger Management Therapy. The measure of dosage is contingent upon the technique of delivery as indicated in the table underneath.

Condition

Dosage

Administration

Drug Resistant Epilepsy

5.0 mg/mL, , 25.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 5.0 mg, 10.0 mg, 2.0 mg, 1.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL

, Oral, Solution - Oral, Solution, Gel, Gel - Rectal, Rectal, Tablet, Tablet - Oral, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, solution, Kit, Liquid - Intramuscular; Intravenous, Liquid, Emulsion, Emulsion - Intramuscular; Intravenous, Solution, concentrate, Solution, concentrate - Oral, Solution - Intramuscular; Intravenous, Injection - Intramuscular, Intramuscular, Injection, Liquid - Intramuscular, Cream - Topical, Cream, Topical, Injection - Intramuscular; Intravenous, Nasal, Spray - Nasal, Spray

Seizures

5.0 mg/mL, , 25.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 5.0 mg, 10.0 mg, 2.0 mg, 1.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL

, Oral, Solution - Oral, Solution, Gel, Gel - Rectal, Rectal, Tablet, Tablet - Oral, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, solution, Kit, Liquid - Intramuscular; Intravenous, Liquid, Emulsion, Emulsion - Intramuscular; Intravenous, Solution, concentrate, Solution, concentrate - Oral, Solution - Intramuscular; Intravenous, Injection - Intramuscular, Intramuscular, Injection, Liquid - Intramuscular, Cream - Topical, Cream, Topical, Injection - Intramuscular; Intravenous, Nasal, Spray - Nasal, Spray

Anger Management Therapy

5.0 mg/mL, , 25.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 5.0 mg, 10.0 mg, 2.0 mg, 1.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL

, Oral, Solution - Oral, Solution, Gel, Gel - Rectal, Rectal, Tablet, Tablet - Oral, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, solution, Kit, Liquid - Intramuscular; Intravenous, Liquid, Emulsion, Emulsion - Intramuscular; Intravenous, Solution, concentrate, Solution, concentrate - Oral, Solution - Intramuscular; Intravenous, Injection - Intramuscular, Intramuscular, Injection, Liquid - Intramuscular, Cream - Topical, Cream, Topical, Injection - Intramuscular; Intravenous, Nasal, Spray - Nasal, Spray

Muscle Tissue

5.0 mg/mL, , 25.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 5.0 mg, 10.0 mg, 2.0 mg, 1.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL

, Oral, Solution - Oral, Solution, Gel, Gel - Rectal, Rectal, Tablet, Tablet - Oral, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, solution, Kit, Liquid - Intramuscular; Intravenous, Liquid, Emulsion, Emulsion - Intramuscular; Intravenous, Solution, concentrate, Solution, concentrate - Oral, Solution - Intramuscular; Intravenous, Injection - Intramuscular, Intramuscular, Injection, Liquid - Intramuscular, Cream - Topical, Cream, Topical, Injection - Intramuscular; Intravenous, Nasal, Spray - Nasal, Spray

Athetosis

5.0 mg/mL, , 25.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 5.0 mg, 10.0 mg, 2.0 mg, 1.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL

, Oral, Solution - Oral, Solution, Gel, Gel - Rectal, Rectal, Tablet, Tablet - Oral, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, solution, Kit, Liquid - Intramuscular; Intravenous, Liquid, Emulsion, Emulsion - Intramuscular; Intravenous, Solution, concentrate, Solution, concentrate - Oral, Solution - Intramuscular; Intravenous, Injection - Intramuscular, Intramuscular, Injection, Liquid - Intramuscular, Cream - Topical, Cream, Topical, Injection - Intramuscular; Intravenous, Nasal, Spray - Nasal, Spray

Lockjaw

5.0 mg/mL, , 25.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 5.0 mg, 10.0 mg, 2.0 mg, 1.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL

, Oral, Solution - Oral, Solution, Gel, Gel - Rectal, Rectal, Tablet, Tablet - Oral, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, solution, Kit, Liquid - Intramuscular; Intravenous, Liquid, Emulsion, Emulsion - Intramuscular; Intravenous, Solution, concentrate, Solution, concentrate - Oral, Solution - Intramuscular; Intravenous, Injection - Intramuscular, Intramuscular, Injection, Liquid - Intramuscular, Cream - Topical, Cream, Topical, Injection - Intramuscular; Intravenous, Nasal, Spray - Nasal, Spray

Syndrome

5.0 mg/mL, , 25.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 5.0 mg, 10.0 mg, 2.0 mg, 1.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL

, Oral, Solution - Oral, Solution, Gel, Gel - Rectal, Rectal, Tablet, Tablet - Oral, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, solution, Kit, Liquid - Intramuscular; Intravenous, Liquid, Emulsion, Emulsion - Intramuscular; Intravenous, Solution, concentrate, Solution, concentrate - Oral, Solution - Intramuscular; Intravenous, Injection - Intramuscular, Intramuscular, Injection, Liquid - Intramuscular, Cream - Topical, Cream, Topical, Injection - Intramuscular; Intravenous, Nasal, Spray - Nasal, Spray

Motor Neuron Disease, Upper

5.0 mg/mL, , 25.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 5.0 mg, 10.0 mg, 2.0 mg, 1.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL

, Oral, Solution - Oral, Solution, Gel, Gel - Rectal, Rectal, Tablet, Tablet - Oral, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, solution, Kit, Liquid - Intramuscular; Intravenous, Liquid, Emulsion, Emulsion - Intramuscular; Intravenous, Solution, concentrate, Solution, concentrate - Oral, Solution - Intramuscular; Intravenous, Injection - Intramuscular, Intramuscular, Injection, Liquid - Intramuscular, Cream - Topical, Cream, Topical, Injection - Intramuscular; Intravenous, Nasal, Spray - Nasal, Spray

Sedation therapy

5.0 mg/mL, , 25.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 5.0 mg, 10.0 mg, 2.0 mg, 1.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL

, Oral, Solution - Oral, Solution, Gel, Gel - Rectal, Rectal, Tablet, Tablet - Oral, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, solution, Kit, Liquid - Intramuscular; Intravenous, Liquid, Emulsion, Emulsion - Intramuscular; Intravenous, Solution, concentrate, Solution, concentrate - Oral, Solution - Intramuscular; Intravenous, Injection - Intramuscular, Intramuscular, Injection, Liquid - Intramuscular, Cream - Topical, Cream, Topical, Injection - Intramuscular; Intravenous, Nasal, Spray - Nasal, Spray

Sedation

5.0 mg/mL, , 25.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 5.0 mg, 10.0 mg, 2.0 mg, 1.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL

, Oral, Solution - Oral, Solution, Gel, Gel - Rectal, Rectal, Tablet, Tablet - Oral, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, solution, Kit, Liquid - Intramuscular; Intravenous, Liquid, Emulsion, Emulsion - Intramuscular; Intravenous, Solution, concentrate, Solution, concentrate - Oral, Solution - Intramuscular; Intravenous, Injection - Intramuscular, Intramuscular, Injection, Liquid - Intramuscular, Cream - Topical, Cream, Topical, Injection - Intramuscular; Intravenous, Nasal, Spray - Nasal, Spray

Generalized Anxiety Disorder

5.0 mg/mL, , 25.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 5.0 mg, 10.0 mg, 2.0 mg, 1.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL

, Oral, Solution - Oral, Solution, Gel, Gel - Rectal, Rectal, Tablet, Tablet - Oral, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, solution, Kit, Liquid - Intramuscular; Intravenous, Liquid, Emulsion, Emulsion - Intramuscular; Intravenous, Solution, concentrate, Solution, concentrate - Oral, Solution - Intramuscular; Intravenous, Injection - Intramuscular, Intramuscular, Injection, Liquid - Intramuscular, Cream - Topical, Cream, Topical, Injection - Intramuscular; Intravenous, Nasal, Spray - Nasal, Spray

Anxiety Disorders

5.0 mg/mL, , 25.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 5.0 mg, 10.0 mg, 2.0 mg, 1.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL

, Oral, Solution - Oral, Solution, Gel, Gel - Rectal, Rectal, Tablet, Tablet - Oral, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, solution, Kit, Liquid - Intramuscular; Intravenous, Liquid, Emulsion, Emulsion - Intramuscular; Intravenous, Solution, concentrate, Solution, concentrate - Oral, Solution - Intramuscular; Intravenous, Injection - Intramuscular, Intramuscular, Injection, Liquid - Intramuscular, Cream - Topical, Cream, Topical, Injection - Intramuscular; Intravenous, Nasal, Spray - Nasal, Spray

Stiff-Person Syndrome

5.0 mg/mL, , 25.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 5.0 mg, 10.0 mg, 2.0 mg, 1.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL

, Oral, Solution - Oral, Solution, Gel, Gel - Rectal, Rectal, Tablet, Tablet - Oral, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, solution, Kit, Liquid - Intramuscular; Intravenous, Liquid, Emulsion, Emulsion - Intramuscular; Intravenous, Solution, concentrate, Solution, concentrate - Oral, Solution - Intramuscular; Intravenous, Injection - Intramuscular, Intramuscular, Injection, Liquid - Intramuscular, Cream - Topical, Cream, Topical, Injection - Intramuscular; Intravenous, Nasal, Spray - Nasal, Spray

Status Epilepticus

5.0 mg/mL, , 25.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 5.0 mg, 10.0 mg, 2.0 mg, 1.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 75.0 mg/mL, 15.0 mg/mL

, Oral, Solution - Oral, Solution, Gel, Gel - Rectal, Rectal, Tablet, Tablet - Oral, Intramuscular; Intravenous, Injection, solution - Intramuscular; Intravenous, Injection, solution, Kit, Liquid - Intramuscular; Intravenous, Liquid, Emulsion, Emulsion - Intramuscular; Intravenous, Solution, concentrate, Solution, concentrate - Oral, Solution - Intramuscular; Intravenous, Injection - Intramuscular, Intramuscular, Injection, Liquid - Intramuscular, Cream - Topical, Cream, Topical, Injection - Intramuscular; Intravenous, Nasal, Spray - Nasal, Spray

Warnings

Diazepam Intensol has six contraindications and should be abstained from when encountering any of the circumstances detailed in the following table.

Diazepam Intensol Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

Obstructive Sleep Apnea (OSA)

Do Not Combine

Glaucoma

Do Not Combine

Myasthenia Gravis

Do Not Combine

Liver Failure

Do Not Combine

Respiratory Insufficiency

Do Not Combine

There are 20 known major drug interactions with Diazepam Intensol.

Common Diazepam Intensol Drug Interactions

Drug Name

Risk Level

Description

Astemizole

Major

The metabolism of Astemizole can be decreased when combined with Diazepam.

Axitinib

Major

The metabolism of Axitinib can be decreased when combined with Diazepam.

Azelastine

Major

Diazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.

Cabazitaxel

Major

The metabolism of Cabazitaxel can be decreased when combined with Diazepam.

Copanlisib

Major

The metabolism of Copanlisib can be decreased when combined with Diazepam.

Diazepam Intensol Toxicity & Overdose Risk

Symptoms of diazepam overdose may include increased drowsiness, unsteadiness, muscle weakness, sleepiness, low blood pressure, slow heartbeat, shaking eyes, and paradoxical excitement. In extreme cases, this may lead to coma, lack of reflexes, breathing problems, and apnea. People with severe respiratory problems may experience more severe effects. Taking diazepam with other substances that can cause drowsiness, such as alcohol, may be fatal. Pregnant women and those breastfeeding should not take diazepam. The drug can pass into breastmilk. Infants under 6 months old should not receive diazepam

image of a doctor in a lab doing drug, clinical research

Diazepam Intensol Novel Uses: Which Conditions Have a Clinical Trial Featuring Diazepam Intensol?

409 active studies are investigating the potential of Diazepam Intensol to manage Anxiety Disorders, Generalized Anxiety Disorder and Stiff Man Syndrome.

Condition

Clinical Trials

Trial Phases

Anxiety Disorders

56 Actively Recruiting

Phase 2, Not Applicable, Phase 4, Phase 3, Early Phase 1

Generalized Anxiety Disorder

183 Actively Recruiting

Not Applicable, Phase 2, Early Phase 1, Phase 4, Phase 1, Phase 3

Syndrome

4 Actively Recruiting

Phase 2, Phase 3, Not Applicable

Lockjaw

0 Actively Recruiting

Stiff-Person Syndrome

4 Actively Recruiting

Phase 2, Phase 1

Sedation

2 Actively Recruiting

Early Phase 1, Not Applicable

Motor Neuron Disease, Upper

0 Actively Recruiting

Athetosis

1 Actively Recruiting

Phase 3

Drug Resistant Epilepsy

1 Actively Recruiting

Not Applicable

Sedation therapy

0 Actively Recruiting

Status Epilepticus

0 Actively Recruiting

Seizures

0 Actively Recruiting

Muscle Tissue

0 Actively Recruiting

Anger Management Therapy

0 Actively Recruiting

Diazepam Intensol Reviews: What are patients saying about Diazepam Intensol?

5

Patient Review

1/27/2010

Diazepam Intensol for Anxious

I've been taking this medication for over 30 years, and recently the effects have lessened. I still experience anxiety and depression even with the dosage of 10mg 3x daily. Are there other options out there that could provide better results?
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about diazepam intensol

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is an Intensol medication?

"Lorazepam Intensol is a medication used to treat anxiety disorders. It may also be used for other purposes not listed in this guide."

Answered by AI

How do you administer diazepam Intensol?

"Use the Intensol as directed by your health care provider.

Draw the amount of Intensol prescribed for a single dose into the dropper. Then, squeeze the dropper contents into a liquid or semi-solid food. Stir the liquid or food gently for a few seconds. The Intensol formulation will blend quickly and completely. Follow the directions given to you by your health care provider when using Intensol."

Answered by AI

What is 5mg of diazepam used for?

"uk Diazepam is commonly used to treat anxiety, muscle spasms and seizures."

Answered by AI

What is lorazepam Intensol used for?

"This medication is used to treat anxiety by enhancing the effects of a natural chemical in the body known as GABA."

Answered by AI

Clinical Trials for Diazepam Intensol

Image of Stanford University School of Medicine in Stanford, United States.

BEAR Program for Suicidal Thoughts

18 - 75
Female
Stanford, CA

The current study aims to test the feasibility of a new form of group therapy for women who have a history of interpersonal trauma and current suicidal ideation. The Building Empowerment and Resilience (BEAR) Therapeutic group has been adapted for women who have experienced trauma and have current suicidal ideation. It incorporates psychological skills, psychoeducation about trauma and gender-based violence, and physical self-defense training, all within a therapeutic process. It will be implemented with women who have experienced interpersonal trauma (physical, sexual, or emotional abuse/neglect) and experience various mental health difficulties, including suicidal ideation. We aim to assess the feasibility to recruit and implement the BEAR group. Our ultimate aim is to assess whether the program can effect self-efficacy and suicidal ideation.

Waitlist Available
Has No Placebo

Stanford University School of Medicine

Jennifer Keller, PhD

Image of Fred Hutch/University of Washington Cancer Consortium in Seattle, United States.

Psilocybin Therapy for Anxiety and Depression in Cancer

18 - 85
All Sexes
Seattle, WA

This phase II trial tests the safety, side effects and how well group retreat psilocybin therapy works for the treatment of anxiety and depression in patients with solid tumors that have spread from where they first started (primary site) to other places in the body (metastatic) or with hematologic cancers for which no treatment is currently available (incurable). For patients with metastatic, incurable cancer, unrelieved anxiety and existential distress can cause profound suffering. Psilocybin therapy can relieve anxiety and existential distress by disrupting patterns of thinking that contribute to anxiety and depression. Psilocybin is a substance being studied in the treatment of anxiety or depression in patients with cancer. In this study, a pharmaceutical grade of psilocybin will be used that has been approved by the FDA for research, provided by Filament Health. Psilocybin acts on the brain by resetting the brain's activity and increasing connections between brain regions, particularly those involved in mood regulation and self-perception. In this study psilocybin is combined with structured discussions and reflections that enable patients to have new insights about their situation. In a prior study, group retreat psilocybin therapy was proven to be safe and this study tests a refined dosing regimen for symptoms of anxiety and depression in patients with metastatic solid tumors or incurable hematologic malignancies.

Phase 2
Waitlist Available

Fred Hutch/University of Washington Cancer Consortium

Anthony Back, MD

Image of Wahwala Iyohlogya/Peaceful Means in Pine Ridge, United States.

Lakota Family Acceptance Program for Depression and Anxiety

Any Age
All Sexes
Pine Ridge, SD

The goal of this open pilot trial (OPT) is to develop a Lakota-adapted Family Acceptance Project (LFAP) for Indigenous 2SLGBTQ+ youth and their caregivers. The OPT is specifically focused on acceptability, feasibility, and safety of programming and research protocols. The investigators will also examine pre- to post- changes on outcomes for the sole purposes of making sure scores on measures are changing in the hypothesized direction (e.g., depression scores are going from moderate to minimal as opposed to no change or depression scores increasing). Once enrolled in the study, participants complete a baseline survey. Then participants will engage in LFAP which is an 8-session group intervention; sessions will be scheduled once a week for eight weeks (at 2 hours per session). Participants will complete survey instruments before and immediately after the program sessions, in addition to post-program surveys and an exit interview.

Recruiting
Has No Placebo

Wahwala Iyohlogya/Peaceful Means (+1 Sites)

Katie Edwards, PhD

Have you considered Diazepam Intensol clinical trials?

We made a collection of clinical trials featuring Diazepam Intensol, we think they might fit your search criteria.
Go to Trials
Image of Seaway Valley Community Health Centre (Cardiac Rehab Program) in Cornwall, Canada.

FRAME for Heart Failure

18+
All Sexes
Cornwall, Canada

Heart failure is a high-risk, chronic condition that impacts patients' mental health. Approximately 50% of heart failure patients experience comorbid mental health conditions, such as stress, depression and anxiety, which affect their day-to-day lives. Despite this interconnection, the integration of mental health awareness and support into cardiac care remains limited. To address this gap, the FRAME (Foundation, Recognition, Awareness, Management, Engagement) intervention was co-designed by researchers, healthcare providers, health system decisionmakers, and patient partners. This pilot study evaluates the feasibility of implementing the FRAME intervention in pilot clinical sites within two health regions in Ontario, Canada, including team-based family medicine clinics, cardiac rehabilitation/specialist clinics, and emergency departments. Utilizing a pretest-posttest hybrid 1 model intervention design, this study evaluates process indicators and patient-focused outcomes through surveys and semi-structured qualitative interviews. Findings from this study will inform a future large scale cohort study and scalable integration of the FRAME tool into existing cardiac care pathways to enhance mental health awareness and support among heart failure patients.

Recruiting
Has No Placebo

Seaway Valley Community Health Centre (Cardiac Rehab Program) (+8 Sites)

Image of Fort Bend ISD in Sugar Land, United States.

Wellbeing Interventions for Anxiety

10 - 20
All Sexes
Sugar Land, TX

The goal of this clinical trial is to learn if psychology and music based interventions can impact anxiety and overall wellbeing in adolescents enrolled in choral music classes. The main questions it aims to answer are: Do specific psychology and music based breathing interventions impact anxiety and overall wellbeing in adolescents? Do specific psychology and music based performance anxiety reduction interventions impact anxiety and overall wellbeing in adolescents? Do specific psychology and music based emotion regulation interventions impact anxiety and overall wellbeing in adolescents? Researchers will compare results of pre-test data, post-test data, qualitative interviews, and surveys of adult choral directors to see if there is a measurable impact on adolescent anxiety and overall wellbeing. Participants will: * Use box breathing during choral music warm-ups to connect choral breathing to breathing for anxiety reduction * Use "magnify" technique to compare cognitive distortions regarding an upcoming performance that may cause anxiety to the most likely realistic outcome * Use emotion regulation through song lyrics technique to connect lyrics of choral music repertoire to participants experienced emotions

Waitlist Available
Has No Placebo

Fort Bend ISD

Jane Kuehne, PhD

Have you considered Diazepam Intensol clinical trials?

We made a collection of clinical trials featuring Diazepam Intensol, we think they might fit your search criteria.
Go to Trials
Image of University of Rochester Medical Center in Rochester, United States.

Deaf CBT-TS for Suicide Risk

18+
All Sexes
Rochester, NY

The goal of this clinical trial is to learn if a short, Zoom-based intervention, Cognitive Behavioral Therapy for Treatment-Seeking for Deaf Individuals (Deaf CBT-TS) can change beliefs about mental health treatment and increase treatment-seeking behaviors in Deaf adults with untreated mental health or alcohol use problems. It will also see if Deaf CBT-TS may reduce suicide risk and explore factors that may increase the effectiveness of Deaf CBT-TS. The main questions it aims to answer are: * Does Deaf CBT-TS increase positive beliefs about treatment and increase treatment-seeking behaviors? * Does Deaf CBT-TS increase hope and reduce mental health symptoms, suicide ideation, and alcohol use? * Is Deaf CBT-TS more effective for individuals with less cultural stress compared to those with high levels of cultural stress? * Is Deaf CBT-TS more effective for Deaf individuals in residential areas with more Deaf resources than those with less Deaf resources? Researchers will compare individuals who complete Deaf CBT-TS to those on a waitlist to see if Deaf CBT-TS works to increase positive beliefs about treatment and treatment-seeking behaviors. Participants will: * Complete a baseline assessment including demographic information, measures of hope, general mental health and functioning, alcohol use, suicide ideation, cultural stress, and beliefs about treatment. * Receive Deaf CBT-TS (2 sessions) or be placed on a waitlist with the option of receiving Deaf CBT-Ts after 4 months * Complete two follow-up assessments in 2 and 4 months.

Waitlist Available
Has No Placebo

University of Rochester Medical Center

Image of Women's Health Concerns Clinic, St. Joseph's Healthcare Hamilton in Hamilton, Canada.

Mindfulness for Postpartum Anxiety

18+
Female
Hamilton, Canada

Postpartum anxiety (PPA) affects up to 20% of mothers in the first year after delivery, with mothers often reporting both psychological and physical symptoms. Present non-pharmacological interventions are effective at improving some psychological aspects of PPA such as anxiety, depressive mood, and distress. However, current interventions are not effective in improving emotion regulation (ER), something that many with PPA experience impairment in. Current interventions also seldom target the physical aspects of anxiety, such as bodily awareness - sensing and understanding internal signals in the body (e.g., sensing a fast heartbeat). There is a link between ER and bodily awareness, however psychological interventions that target both these aspects have not been investigated in the PPA population. As a result, a mind-body intervention targeting both ER and bodily awareness is needed to offer a more holistic treatment option. The purpose of the proposed study is to test the effectiveness of a 4-week mindfulness intervention on anxiety symptoms, ER, and bodily awareness in those with PPA. We will use self-report questionnaires alongside brain imaging (functional magnetic resonance imaging; fMRI) to evaluate the effectiveness. Combining both subjective and objective measures will provide greater confidence in our findings, ensuring a more comprehensive understanding of the intervention's impact. Self-report questionnaires will be administered at enrolment, immediately post-intervention, and 4 weeks post-intervention. Brain imaging will be conducted at enrolment and immediately post-intervention. We believe this intervention will lead to improvements in anxiety symptoms, ER, and bodily awareness on the questionnaires and fMRI scans. If effective, the proposed mindfulness intervention will target a broader range of psychological and physical symptoms, and reduce the negative impact of PPA on mothers and their infants in Canada and beyond.

Recruiting
Has No Placebo

Women's Health Concerns Clinic, St. Joseph's Healthcare Hamilton (+1 Sites)

Sheryl M Green, Ph.D., C.Psych

Image of Cedars-Sinai Medical Center in Los Angeles, United States.

Living Well Program for Anxiety in Breast Cancer

18+
Female
Los Angeles, CA

The goal of this study is to evaluate the efficacy and cost-effectiveness of the Living Well Program, a digital therapeutic application with telecoaching support, in breast cancer patients with moderate-to-severe anxiety. The main question the study aims to answer is: does digital cognitive-behavioral therapy-based interventions decrease the overall healthcare costs of patients with stage II to IV breast cancer? The study has one group of participants who will use the Living Well app and telecoaching support. This group will be compared to retroactively matched controls. Over 3 months, patients will complete 21 mental health modules and 5 telecoaching sessions. In the following 3 months, they will complete any outstanding telecoaching sessions and modules while still being monitored, even if they finished all modules and sessions in the first 3 months. The 6 months after that will be the follow-up phase. They will still have access to the Living Well app and may continue to use it, and they will complete the same assessment questionnaires as baseline to identify any changes in their overall mental health.

Waitlist Available
Has No Placebo

Cedars-Sinai Medical Center

Scott Irwin, MD

Have you considered Diazepam Intensol clinical trials?

We made a collection of clinical trials featuring Diazepam Intensol, we think they might fit your search criteria.
Go to Trials